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Abstract Yokukansan (YKS) has been used in Japan as a
remedy for neurosis, insomnia, and children with night
crying. In a previous study, we reported that YKS controls
scratching behavior and inhibits the development of atopic
dermatitis (AD)-like lesions in NC/Nga mice. In this study,
we investigated the effects of YKS on the development of
AD-like lesions in socially isolated NC/Nga mice com-
pared with the effects of fexofenadine and elucidated the
mechanism of the ameliorating effect of YKS on the skin
lesions. Ten-week-old male NC/Nga mice were divided
into three groups (n = 5/group): the conventional control,
the YKS-treated, and the fexofenadine-treated groups, and
were kept isolated under conventional conditions for
6 weeks. Measurements were made of dermatitis scores
and transepidermal water loss (TEWL), scratching and
grooming behaviors. Immunohistochemistry and mRNA
levels were also evaluated. We performed similar experi-
ments under speciﬁc pathogen free (SPF) conditions that
served as a SPF control. YKS and fexofenadine inhibited
the aggravation of skin lesions and decreased TEWL, but
only YKS decreased the numbers of scratching and path-
ologic grooming behaviors. Immunohistochemistry and
RT-PCR revealed that N-methyl-D-aspartate (NMDA)
receptor expression was increased in the skin of conven-
tional control mice and was decreased in YKS-treated
mice. Glutamate transporter-1 (GLT-1) mRNA levels were
decreased in the skin of conventional control mice and
were increased in YKS-treated mice. The results indicate
that YKS ameliorates AD-like skin lesions in NC/Nga mice
through a mechanism distinct from that of fexofenadine.
Furthermore, the effects of YKS are suggested to be
mediated via glutamate signaling in the skin lesions.
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Abbreviations
AD Atopic dermatitis
GLT-1 Glutamate transporter 1
NMDA receptor N-methyl-D-aspartate receptor
SPF Speciﬁc pathogen free
TEWL Transepidermal water loss
YKS Yokukansan
Introduction
Atopic dermatitis (AD) is a chronic relapsing eczematous
skin disease characterized by pruritus and inﬂammation
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DOI 10.1007/s00403-011-1137-9with cutaneous physiological dysfunction. Long-lasting
itching is an intolerable sensation for patients with severe
AD. Psychosocial stresses such as human relationships,
pressures of work, worries about career, and anxieties for
independence affect the skin condition of patients with AD.
Such patients tend to have habitual scratching behavior
called ‘‘addictive scratching’’ or ‘‘scratch dependence’’;
this behavior worsens their eruptions gradually and forms a
vicious cycle called the ‘itch-scratch cycle’. Therefore,
treatments are necessary for both the physical and the
mental conditions of the patients [1, 2]. We term these
adverse conditions of AD as ‘‘behavioral and psychological
symptoms of atopic dermatitis (BPSA)’’, and it has become
an issue of public concern. Effective anti-pruritic and anti-
BPSA drugs are needed by intractable AD patients.
NC/Nga mice have been regarded as an excellent model
for AD since they develop AD-like skin lesions sponta-
neously under conventional conditions, but not under spe-
ciﬁc pathogen free (SPF) conditions [3]. Before starting the
present study, we assessed the effects of the environment
and stress on the skin of NC/Nga mice by comparing the
mice bred in groups with those that were kept isolated
under conventional conditions and under SPF conditions,
respectively. It is well known that individually housed mice
undergo strong social stress because mice are social ani-
mals that live in groups in the natural environment. Mea-
surements were made of dermatitis scores, transepidermal
water loss (TEWL), scratching behaviors as well as
grooming behaviors. Under SPF conditions, dermatitis was
not observed either in the group housed or the individually
housed animals. In that study, we used data derived from
the isolated mice kept under SPF conditions as a SPF
control, which had no skin lesions. The results showed that
isolated NC/Nga mice kept under conventional conditions
manifested the most severe dermatitis with increased
scratching behaviors and pathological grooming behaviors
(data not shown). We concluded that socially isolated NC/
Nga mice kept under conventional conditions exhibit skin
lesions similar to those of human AD patients with BPSA
under stressful conditions.
Previously, our group [4] reported that Paroxetine, a
selective serotonin re-uptake inhibitor (SSRI), inhibits the
development of AD-like lesions in NC/Nga mice. We
expected that Paroxetine might be an alternative or com-
plementary therapeutic option for the treatment of AD.
Previous studies have indicated that centrally acting ther-
apeutic drugs are useful for anti-pruritic therapy.
Yokukansan (YKS) is a traditional Japanese medicine
called Kampo medicine. In Japan, Kampo medicines are
often used for AD patients who do not respond to existing
drugs or want to avoid using topical steroid ointment.
Although Kampo medicines have long been used for many
AD patients, there is no sufﬁcient evidence about their
efﬁcacy so far. The reason is that Kampo medicines are
usually prescribed individually for patients according to
their symptoms, called ‘‘shou’’, and therefore it is difﬁcult
to perform large-scale clinical studies using Kampo med-
icines. Recently, however, several studies have been per-
formed using Kampo medicines and evidence-based data
are now available. For example, Kobayashi et al. [5]
reported that Hoshu-ekki-to is effective and safe for AD
patients using multicenter, double-blind, randomized, pla-
cebo-controlled studies. Gao et al. [6] reported that Juzen-
taiho-to, Hochu-ekki-to, Shofu-san and Oren-gedoku-to
might correct the Th1/Th2 balance skewed to Th2, and thus
inhibit dermatitis in NC/Nga mice. With this background,
we examined the efﬁcacy of YKS in the treatment of skin
lesions in NC/Nga mice to obtain basic information
regarding the treatment of AD in humans.
YKS has been used as an anti-anxiety agent to treat
neurosis, insomnia, and children with night crying. Clini-
cally, it has been reported that YKS ameliorates excite-
ment, anger, and hallucinations in behavioral and
psychological symptoms of dementia (BPSD), and in
patients with Alzheimer’s disease. BPSD treatment with
YKS has been successful in clinical cases of dementia with
Lewy bodies, Parkinsonian dementia, other forms of senile
dementia, and also is successful in treating cases of neu-
ropathic pain, schizophrenia, and restless legs syndrome
[7–14]. Thus, YKS is a notable Kampo medicine in various
ﬁelds.
In our previous study using NC/Nga mice, YKS-con-
trolled scratching behaviors inhibited the development of
AD-like lesions and showed a ‘‘preventive effect’’ as well
as a ‘‘therapeutic effect’’ on dermatitis [15]. However, the
mechanism by which YKS controls scratching behaviors
and inhibits the development of AD-like lesions in NC/Nga
mice remains unexplored. In the present study, we inves-
tigated the effects of YKS on the development of AD-like
lesions in socially isolated NC/Nga mice and compared its
effects with those of fexofenadine, a histamine H1-receptor
antagonist.
Materials and methods
Animals
Since female NC/Nga mice have few skin lesions, male
NC/Nga mice were used for this study. Male NC/Nga mice
(10 weeks of age) were purchased from Japan SLC Inc.
(Shizuoka, Japan) and were maintained under conventional
conditions. The mice were divided into three groups: the
control, the YKS-treated and the fexofenadine-treated
groups (n = 5 per group). The mice were individually
housed (under social isolation stress) throughout the
660 Arch Dermatol Res (2011) 303:659–667
123experiment. We only used NC/Nga mice which had mild
skin lesions for the experiments and mice with less severe
or more severe lesions were excluded. The animal room
was maintained at 24 ± 2C, 55 ± 10% relative humid-
ity, and a 12–12 h light–dark cycle. All mice were
allowed access to water and food ad libitum. The indi-
vidual cage size was 9(w) 9 13(h) 9 20(d) cm. All pro-
cedures performed on animals were approved by the
Institutional Animal Care and Use Committee (IACUC)
of Juntendo University, with the approval number of
220014.
Drugs
YKS, supplied by Tsumura & Co. (Tokyo, Japan), is a
vacuum-concentrated extract of seven herbs in the fol-
lowing ratio: 4.0 g Atractylodes lancea rhizome, 4.0 g
Hoelen, 3.0 g Cnidium rhizome, 3.0 g Japanese Angelica
root, 2.0 g Bupleurum root, 1.5 g Glycyrrhiza root, and
3.0 g Uncaria thorn. Each plant material was authenticated
by identiﬁcation of external morphology and marker
compounds of plant specimens according to the methods of
the Japanese Pharmacopoeia and the Tsumura standard.
The seven medicinal herbs were extracted with puriﬁed
water at 95C for 1 h, and the extraction solution was
separated from the insoluble waste and was concentrated
by removing water under reduced pressure. The spray-
drying technique was used to produce a dried extract
powder. Mice were given water containing YKS (Lot
No.2060054010) at the dosage of 0.6% (1.0 g/kg). The
control mice were given drug-free water ad libitum.
Fexofenadine hydrochloride was supplied by LKT Labo-
ratories, Inc. (Saint Paul, MN, USA) and dissolved at
0.03% (40 mg/kg), and was also provided to mice in water
ad libitum.
Evaluation of the severity of dermatitis and observation
of grooming behaviors
The severity of skin lesions was examined and scored at 0,
1, 3 and 6 weeks. Skin lesions on the dorsal skin were
assessed according to the following four symptoms: ery-
thema, edema, erosion and dryness, and the sum was
considered as the individual score (0: no symptom, 1: mild,
2: moderate, 3: severe). The frequency of grooming
behaviors was counted in a 10 min observation period.
These assessments were performed by at least two
investigators.
Measurement of scratching behaviors
Scratching behaviors of the hind paws were detected and
evaluated using a Microact
 (Neuroscience, Tokyo,
Japan). Under ether anesthesia, a small Teﬂon-coated
magnet (1 mm in diameter, 3 mm long) was implanted
subcutaneously into the dorsal side of both hind paws of
each mouse the day before the ﬁrst recording of scratching
behaviors. The magnet remained in situ throughout the
entire experimental period. If the magnet was dislocated, it
was implanted again. Each mouse with magnets was placed
in the observation chamber (11 cm in diameter, 18 cm
high) surrounded by a round coil. Movement of the hind
paws with implanted magnets induced an electric current in
the coil, which was ampliﬁed and recorded by the Micro-
act
 software. The number of scratching behaviors was
measured for 24 h. In NC/Nga mice, long-lasting scratch-
ing behaviors ([1.5 s) are more important than short-last-
ing scratching behaviors (0.3–1.5 s) [16], so the number of
long-lasting scratching behaviors was counted.
Measurement of transepidermal water loss on the dorsal
skin
The hair on the dorsal skin of each mouse was shaved using
an electric razor under ether anesthesia and TEWL was
measured using a mobile Tewameter
 MSC100/TM300
(Courage & Khazaka, Koeln, Germany) at 0, 1, 3 and
6 weeks. The values were recorded when stabilized
approximately 10 s after the probe had been placed on the
skin. TEWL was measured three times for each mouse and
the mean values were obtained.
Quantitative real-time PCR
The dorsal skin of each mouse was excised using a
surgical knife and was homogenized using a SK-100
(Tokken, Chiba, Japan), and total RNA was extracted
using QIAzol (Qiagen, Hilden, Germany). cDNAs were
synthesized using a high capacity cDNA reverse tran-
scription kit (Applied Biosystems, Foster City, CA, USA)
according to the manufacturer’s instructions. Quantitative
real-time PCR was done with Taqman universal PCR
master mix, using an Applied Biosystems 7500 real-time
PCR system (Applied Biosystems). Taqman probes and
primers were purchased from Applied Biosystems. The
expression of mRNA in each mouse was normalized to
the expression of mouse b-actin mRNA as the endoge-
nous control.
Histopathology
Formalin-ﬁxed, parafﬁn-embedded skin samples from each
mouse were sectioned and stained with hematoxylin and
eosin. Skin samples were also stained with toluidine blue
for identiﬁcation of mast cells. Representative sections
were observed at 109 magniﬁcation.
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All mouse tissues were sliced as frozen sections at 5 lm
thickness. Detection of mouse NMDA receptors was car-
ried out using anti-NMDARf1(C-20) goat polyclonal
antibodies supplied by Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA, USA). The goat polyclonal antibodies
were raised against the peptide corresponding to the car-
boxy terminus of the human glutamate (NMDA) recep-
torf1. That human sequence is identical with the sequences
of mice and rats. Binding of the primary antibody was
detected using the ﬂuorescent anti-goat secondary antibody
(Alexa Fluor & reg
 488 goat anti-rabbit IgG (H ? L),
Molecular Probes, Inc., Eugene, OR). Nuclei were stained
with DAPI using ProLong
 Gold anti-fade reagent
(Molecular Probes, Inc.). Images were obtained using a
confocal laser scanning microscope (FluoView FV1000
Confocal Microscope, Olympus Corporation, Tokyo,
Japan).
Statistical analyses
All data are presented as means ± SE. Statistical com-
parison of real-time PCR was analyzed using the Wilcoxon
test. For other results, statistical analysis was performed
using one-way ANOVA followed by Bonferroni/Dunn test.
P values of\0.05 are deﬁned as statistically signiﬁcant.
Results
Time courses of dermatitis scores, TEWL
and the numbers of scratching behaviors and grooming
behaviors
Dermatitis scores of the conventional control group were
aggravated as time goes on. Both the YKS- and the fexo-
fenadine-treated groups signiﬁcantly inhibited the aggra-
vation of skin lesions in NC/Nga mice from 3 weeks after
the start of the experiments. The dermatitis score of the
SPF control group was not more than a minor increase
(Fig. 1a). The TEWL of the conventional control group
was increased as time goes on. The YKS- and the fexo-
fenadine-treated groups signiﬁcantly inhibited the increase
of TEWL compared with the conventional control mice
from 3 weeks. The TEWL of the SPF group, which had no
skin lesions, was not increased (Fig. 1b). Scratching
behaviors of the conventional control and the fexofena-
dine-treated groups increased as time goes on. The YKS-
treated group signiﬁcantly decreased the scratching
behaviors compared with the conventional control group
after 6 weeks. The scratching behaviors of the SPF group
was not increased (Fig. 1c). Grooming behaviors of the
conventional control group and the fexofenadine-treated
group were increased under social isolated conditions. The
YKS-treated group signiﬁcantly decreased the grooming
behaviors compared to the conventional control mice from
3 weeks. The grooming behaviors of the SPF group
increased under social isolated conditions (Fig. 1d).
Assessment of the number of inﬁltrating mast cells
in the skin of NC/Nga mice
Using histological examination, the numbers of mast cells
inﬁltrating the skin were enumerated. The numbers of
inﬁltrating mast cells in 0.25 9 0.25 mm (0.0625 mm
2)
squares were counted using a microscope. The numbers of
inﬁltrating mast cells in the YKS-treated or the fexofena-
dine-treated mice were signiﬁcantly decreased compared
with the conventional control mice (Fig. 2).
Immunohistochemical staining of NMDA receptors
in the skin of NC/Nga mice
At the involved-skin lesion, expression of NMDA receptors
were increased in the epidermis under the conventional
control mice compared with the SPF control mice. After the
treatment with YKS, the expression of NMDA receptors
was signiﬁcantly reduced in the conventional control mice,
which was similar to that of SPF control mice (Fig. 3).
RT-PCR analyses of NMDA receptor, glutamate
aspartate transporter, excitatory amino-acid carrier
1 and glutamate transporter-1 in the skin of NC/Nga
mice
The level of NMDA receptor mRNA in the skin was sig-
niﬁcantly increased in the conventional control mice
compared with the SPF control mice, and was signiﬁcantly
decreased in the YKS-treated mice compared with the
conventional control mice. The level of glutamate trans-
porter-1 (GLT-1) mRNA in the skin was decreased in the
conventional control mice compared with the SPF control
mice and the YKS-treated mice. The levels of glutamate
aspartate transporter (GLAST) and excitatory amino-acid
carrier 1 (EAAC1) mRNAs were not signiﬁcantly different
among the four groups (Fig. 4).
Discussion
The results of the present study demonstrate that the tra-
ditional Japanese medicine, YKS, ameliorates the devel-
opment of AD-like lesions and the increase in TEWL and
also decreases the number of scratching behaviors and
pathological grooming behaviors in socially isolated NC/
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1 in the skin are involved in the AD-like skin lesions of
NC/Nga mice. YKS ameliorated the AD-like skin lesions
as well as fexofenadine as shown in the present study. In
our previous study, we demonstrated that YKS ameliorates
the AD-like skin lesions in a dose-dependent manner in
NC/Nga mice [15]. In the present study, we utilized a
Microact
 to count the scratching behaviors of the animals,
which provides a more objective and accurate evaluation of
scratching behaviors as compared with visual counting by
the investigators. Long-lasting ([1.5 s) scratching behav-
iors were counted, so that scratching behaviors which are
equivalent to human ‘‘addictive scratching’’ were evalu-
ated in NC/Nga mice [16]. YKS signiﬁcantly inhibited
scratching behaviors compared with the conventional
control mice and the fexofenadine-treated mice in which
the numbers of scratching behaviors gradually increased.
Although grooming behaviors are intrinsically essential in
many animal species, anxiety and/or stress induce(s) the
increase in involuntary grooming behaviors, which leads to
inﬂammation, erosion, and/or ulceration in the skin. Such
behaviors are also known to increase in mice that are
models for obsessive compulsive disorder [17–19].
Obsessive–compulsive disorder is an anxiety disorder and
is characterized by persistent intrusive thoughts (obses-
sions) and repetitive behaviors (compulsions). Our exper-
imental results show that YKS reduces the numbers of
aberrant grooming behaviors compared with the conven-
tional control mice and the fexofenadine-treated mice, i.e.,
it was shown that YKS alleviates excessive anxiety and/or
stress in NC/Nga mice. Our experimental results suggest
that YKS acts on the central nervous system (CNS)
inducing a tranquilizing effect.
Itching is one of the major diagnostic criteria of AD and
is also one of the most troublesome symptoms in AD [1, 2].
The discomfort of itching causes anger and irritation in AD
patients and in family members. The itching sensation
disturbs sleep, work, school and social life in AD patients
Fig. 1 The effects of YKS and fexofenadine on dermatitis score (a),
TEWL (b), the numbers of scratching behaviors (c) and grooming
behaviors (d) for AD-like skin lesions in NC/Nga mice. a The skin
lesions of the conventional control group were aggravated as time
goes on. Both the YKS- and the fexofenadine-treated groups
signiﬁcantly inhibited the aggravation of skin lesions in NC/Nga
mice from 3 weeks after the start of the experiments. The dermatitis
score of the SPF control group was not more than a minor increase.
b The TEWL of the conventional control group was increased as time
goes on. The YKS- and the fexofenadine-treated groups signiﬁcantly
inhibited the increase of TEWL compared with the conventional
control mice from 3 weeks. The TEWL of the SPF group, which had
no skin lesions, was not increased. c Scratching behaviors of the
conventional control and the fexofenadine-treated groups increased as
time goes on. The YKS-treated group signiﬁcantly decreased the
scratching behaviors compared with the conventional control group
after 6 weeks. The scratching behaviors of the SPF group were not
increased. d Grooming behaviors of the conventional control group
and also the fexofenadine-treated group were increased under social
isolated conditions. The YKS-treated group signiﬁcantly decreased
the grooming behaviors compared with the conventional control mice
from 3 weeks. The grooming behaviors of the SPF group increased
under social isolated conditions. SPF control: unﬁlled circle,
conventional control: ﬁlled circle, YKS: ﬁlled square, fexofenadine:
ﬁlled triangle. Data are presented as means ± SE (n = 5–6).

p\0.05,
p\0.01 vsersu SPF control, *p\0.05, **p\0.01
versus conventional control, one-way ANOVA followed by Bonfer-
roni/Dunn test
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123for a long period of time, and eventually their quality of life
(QOL) will be debased. The effective control of itching
will contribute to controlling the skin lesions and to
improving the patients’ QOL. The purpose of our study
was to suppress the intolerable itching sensations which are
not readily cured.
YKS, a traditional Japanese medicine, has been used as
a remedy for neurosis, insomnia, and children with night
crying. Since Iwasaki et al. [7] reported that YKS is
effective for treating BPSD in a randomized, observer-
blind, controlled trial in 2005, many basic and clinical
studies using YKS have been reported. Clinically, it has
been reported that YKS ameliorates excitement, anger, and
hallucinations in BPSD, and in patients with Alzheimer’s
disease. Treatment of BPSD with YKS has been successful
in clinical cases of dementia with Lewy bodies, Parkinso-
nian dementia and other forms of senile dementia, and also
treatments of neuropathic pain, schizophrenia and restless
legs syndrome with YKS have been successful [7–14].
Basic research has shown that YKS regulates both sero-
tonin signaling and glutamate signaling. Serotonin is made
from tryptophan and suppresses the excitement of neuronal
cells. Serotonin receptors now number more than 14, one
of them being the 5-HT1A receptor. YKS is a partial
agonist of the 5-HT1A receptor, and down-regulates the
5-HT2A receptor. Terawaki et al. [20] stated that YKS is a
partial agonist of 5-HT1A receptors. Egashira et al. [21]
stated that YKS is down-regulated the 5-HT2A receptor.
Kawana et al. [22] reported that 5-HT1A receptors agonist
is effective for AD patients. This report suggests that YKS
which has partial agonist effect of 5-HT1A receptors is
effective for AD patients. Glutamate is a major excitatory
neurotransmitter, and accounts for 70–80% of neurotrans-
mitters in the CNS. Glutamate is related to cognition,
Fig. 2 Effects of YKS and fexofenadine on the numbers of
inﬁltrating mast cells in the skin of NC/Nga mice The numbers of
mast cells in the skin of NC/Nga mice skin inside a 0.25 9 0.25 mm
(0.0625 mm
2) square were counted using a microscope. The numbers
of mast cells of the conventional control group were signiﬁcantly
increased compared with the numbers of mast cells in the SPF control
group. The numbers of mast cells of the YKS- and the fexofenadine-
treated groups were signiﬁcantly decreased compared with the
numbers of mast cells in the conventional control group. Data are
presented as means ± SE (n = 5–6).
p\0.05,
p\0.01 versus
SPF control, *p\0.05, **p\0.01 versus conventional control, one-
way ANOVA followed by Bonferroni/Dunn test
Fig. 3 Immunohistochemical
analysis of NMDA receptor
expression in the skin of NC/
Nga mice Sections were stained
with a ﬂuorescent anti-goat
secondary antibody (Alexa
Fluor
 Anti-Goat IgG) (green).
Nuclei were counterstained with
40-60-diamidino-2-phenylindole
hydrochloride (DAPI) (blue).
NMDA receptor expression in
the conventional control was
increased compared with the
SPF control. NMDA receptor
expression in the YKS group
was decreased compared with
the conventional control and the
fexofenadine groups. The scale
bar represents 100 lm
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tamate itself has excitotoxicity and is related to several
psychoses [23, 24]. Ikarashi et al. [25] reported that YKS
inhibits glutamate-mediated excitotoxicity as one of its
mechanisms of action. Kawakami et al. [23, 24] reported
that YKS binds antagonistically to NMDA receptors and
exerts a neuroprotective effect against glutamate-induced
excitotoxicity, using cultured rat cortical astrocytes. Hir-
atsuka et al. [26] explained clearly that YKS inhibits
neuronal death during ER stress by regulating the unfolded
protein response. Accordingly, YKS controls extracellular
glutamate concentrations by suppressing NMDA receptors
and activating glutamate transport, and by suppressing
glutamate-mediated excitotoxicity and ER stress, and ulti-
mately inhibiting neuronal death in the CNS. Uchida et al.
[27] reported that the effects of YKS might be mediated by
inhibiting the activity of the dopaminergic system. Thus,
YKS has beneﬁcial effects on BPSD and on various psy-
choses [28, 29].
Furthermore, it has become clear that glutamate signaling
also functions in non -neuronal tissues and occurs in sites as
diverse as bone, pancreas, and skin [30, 31]. It was reported
by Langerstrom et al. that vesicular glutamate transporters
(VGLUT2) regulate the chronic itch sensation in mice [32].
Intriguingly, Skerry and Genever [31] reported that kerati-
nocytes, dermal ﬁbroblasts, melanocytes and Merkel cells
also express glutamate transporters and NMDA receptors.
They also reported that NMDA receptors are expressed on
keratinocytes, and GLAST and GLT-1 are expressed by
ﬁbroblasts.OurexperimentalresultsindicatethatYKSmight
haveeffectsonNMDAreceptorsandGLT-1,i.e.,YKSmight
act on keratinocytes and/or ﬁbroblasts. In addition, Fuziwara
et al. and others [9, 33–36] reported that glutamate plays an
important role as a signal in cutaneous barrier homeostasis
and in epidermal hyperplasia induced by barrier disruption.
WepostulatethatYKSmightaffectglutamatetransportsand
NMDA receptors in the skin, and thus might ameliorate
homeostasis of the skin. YKS activates glutamate transport
and reduces free glutamate among neurons. Thus, we
examinedthe effectsofYKSon dermatitisina mousemodel
for AD, NC/Nga mice. In addition, when AD-like lesions in
NC/Nga mice worsen, the glutamate concentration in nerve
terminalsisexpectedtobehighduetotheinhibitionofGLT-
1 activation. YKS might activate GLT-1, and the extracel-
lular concentration of glutamate would be normalized as a
result. It is expected that YKS would suppress glutamate-
mediated cytotoxicity, and would normalize keratinocytes
and ameliorate AD-like lesions in NC/Nga mice.
Our previous study showed that YKS controls scratching
behaviors and inhibits the development of AD-like lesions
in isolated NC/Nga mice. In the present study, we com-
pared the efﬁcacy of YKS and fexofenadine using the same
Fig. 4 RT-PCR analyses of GLAST, EAAC1, GLT-1 and NMDA
receptor mRNA levels in the skin of NC/Nga mice RT-PCR analyses
of total RNAs extracted from the skins of NC/Nga mice. NMDA
receptor mRNA levels in the skin were signiﬁcantly increased in the
conventional control NC/Nga mice compared with the SPF control
mice. YKS treatment signiﬁcantly decreased the elevated NMDA
receptor mRNA levels compared with the conventional control NC/
Nga mice. GLT-1 mRNA levels in the skin were signiﬁcantly
decreased in the conventional NC/Nga mice control mice compared
with the SPF control mice. YKS treatment signiﬁcantly increased the
GLT-1 mRNA levels compared with the conventional control mice.
Data are presented as means ± SE (n = 5–6).
p\0.05,
p\0.01
versus SPF control, *p\0.05, **p\0.01 versus conventional
control, Wilcoxon’s test
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123experimental system. Both YKS and fexofenadine inhibit
the aggravation of AD-like symptoms in socially isolated
NC/Nga mice with respect to TEWL and dermatitis scores.
However, YKS decreases the scratching and grooming
behaviors in socially isolated NC/Nga mice. Thus, we
speculate that YKS inhibits the aggravation of AD-like
skin lesions in isolated NC/Nga mice due to mechanisms
different from fexofenadine. According to the immuno-
histological study and RT-PCR for NMDA receptors and
GLT-1, YKS has a tendency to decrease the mRNA levels
of NMDA receptors and to increase the mRNA levels of
GLT-1. Thus, YKS is an excellent cell excitement modu-
lator due to its regulation of intracellular glutamate con-
centrations in the skin.
Several studies analyzed the function of NMDA recep-
tors in the skin. NMDA receptors reside on keratinocytes
and are known to be involved in regulating their prolifer-
ation and differentiation and in skin barrier repair [30, 31,
33, 34]. The role of GLT-1 which resides on keratinocytes
and ﬁbroblasts in the skin is not well understood. From
literature on the function of NMDA receptor in the skin,
when aggravating AD-like lesions occur in NC/Nga mice,
the NMDA receptors may be activated and stimulate the
keratinocytes, so that skin barrier repair is delayed. YKS
inhibits NMDA receptor activity, thus skin barrier repair
might be normalized. Further, YKS ameliorates the
development of AD-like lesions in NC/Nga mice.
In conclusion, the present study suggests that YKS
ameliorates the development of AD-like skin lesions and
scratching behaviors in NC/Nga mice due to a mechanism
different from fexofenadine. YKS suppresses the activity
of NMDA receptors and enhances the activity of GLT-1 in
the skin. We expect that YKS inhibits NMDA receptors
and activates GLT-1 by adjusting the extracellular con-
centration of glutamate in the skin of NC/Nga mice. Fur-
ther study is necessary to characterize the mechanism(s) of
glutamate signaling and the relationship between the itch
sensation and glutamate signaling function in the skin of
NC/Nga mice. The authors plan to investigate the role of
glutamate in the induction of itch sensation in future
experiments. This study showed that YKS was effective for
treating AD-like skin lesions with NC/Nga mice, and might
be a useful therapeutic strategy for AD patients with BPSA
under stressful conditions. In addition, we disclosed the
glutamate signaling pathway involved in the AD-like skin
lesions with NC/Nga mice.
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